| abstract |
Disclosed are methods of treating lupus erythematosus in humans. Specific methods encompass the administration of (+) - 2- [1- (3-ethoxy-4-methoxyphenyl) -2-methylsulfonylethyl] -4-acetylaminoisoindoline-1,3-dione, 4- (amino) -2- (2.6 -dioxo (3-piperidyl)) isoindolin-1,3-dione (ACTIMID ™), 3- (4-amino-1-oxo-1,3-dihydroisoindol-2-yl) piperidin-2,6-dione (REVLIMID ) or cyclopropyl {2 - [(1S) -1- (3-ethoxy-4-methoxyphenyl) -2- (methylsulfonyl) ethyl] -3-oxoisoindolin-4-yl} carboxamide, per se, or alternatively, in combination with a second active agent. |